Form 4: ALX Oncology Director Rekha Hemrajani Acquires 30,000 Shares

Director Rekha Hemrajani of ALX Oncology Holdings Inc. purchased 30,000 shares of common stock at a weighted average price of $1.5468 per share.

Summary

• Rekha Hemrajani, a director at ALX Oncology Holdings Inc., acquired 30,000 shares of common stock on December 2, 2024.
• The shares were purchased at a weighted average price of $1.5468 per share.
• The transactions occurred at prices ranging from $1.515 to $1.55.
• Following the transaction, Ms. Hemrajani directly owns 33,000 shares of ALX Oncology stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares is generally a good sign, but it's a routine transaction and not a major event.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for a director's purchase of shares and is similar to filings from other companies in the biotechnology sector.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

ALX Oncology, insider trading, share purchase, Form 4, director, equity, stock